Syntheses of specifically functionalized molecules continue to be rate limiting steps (RLS) in drug discovery. Improvement in this RLS means investing only in reactions/synthetic sequences that are more likely to succeed. Structural diversifications, different substitution patterns or unique heterocyclic systems can often adversely impact the crucial step(s) of established synthetic sequences or development of feasible …Read More >

INNOVATION THAT MATTERS By Rich Soll, Senior Advisor, Strategic Initiatives at WuXi AppTec (@richsollwx) Synthetic chemist Joseph Ready believes a huge amount of innovation in the drug industry comes from academia. Academic science is arguably the greatest source of innovation in our ecosystem, yet faces challenges when considering the transition from the lab to early stage …Read More >

In the past, thousands of proteins were considered undruggable. The restricted number of chemical entities available and classical methods limited the exploration of this undevelopable area. Today, the combination of novel chemical modalities and advanced technical approaches has resulted in new clinical candidates from previously undruggable targets. To accelerate your drug discovery campaign, WuXi AppTec´s …Read More >

Integrated Services BIOLOGY & PHARMACOLOGY BINARY/TERNARY COMPLEX FORMATION Biochemical & Biophysical Assays Biochemical binding assay Cellular Assays TARGET UBIQUITINATION & DEGRADATION In vitro Assays-Target ubiquitination Target degradation assay PK/PD Animal Disease Model Evaluation CHEMISTRY Specific virtual library design Compound synthesis Conjugation and all type of custom syntheses from milligram to kilogram scale Purification and analytical …Read More >

Biomarker discovery Mouse clinical trial 61 PDX-derived primary cancer cell lines Drug-resistant xenograft models Combination therapy platform including radiation World leading genome sequencing and bioinformatics capability

One of the largest collection of Patient-Derived Xenograft (PDX) Tumor Models in Asia with gene expression/mutation profiling 1200 PDX models Collection of PDX models prevalent in Asia 800+ PDX models with genetic profiling Searchable online database with mobile APP Integrated online database for PDX, CDX & Syngeneic tumor models with mobile App PDX with oncogene …Read More >

Immuno-oncology Platform An outstanding platform to enable cancer immunotherapy with one stop service: Immunological function assessment TIL analysis – Flowcytometry, Multiplex IF and Cytex Animal models – Syngeneic and humanized models Immune profiling by NGS – Single Cell RNAseq, Mutation burden and TCR/BCR repertoire Clinical biomarker services – CAP certification and GCP compliance

A large collection of cell line-derived xenograft (CDX) tumor models 215 validated models, SOC data available World leading imaging based orthotopic/metastatic CDX platform 28 models covering 16 tumor types